Correction to HLA-A24:02 increase the risk of allopurinol-induced drug reaction with eosinophilia and systemic symptoms (DRESS) in HLA-B58:01 carriers in Korean population; A multicenter cross-sectional case-control study

IF 4.6 2区医学 Q2 ALLERGY

Clinical and Translational Allergy Pub Date : 2024-04-05 DOI:10.1002/clt2.12351

引用次数: 0

Abstract

M. Y. Kim, J. Yun, D. Y. Kang, T. H. Kim, M. K. Oh, S. Lee, et al. HLA-A* 24: 02 increase the risk of allopurinol-induced drug reaction with eosinophilia and systemic symptoms in HLA-B* 58: 01 carriers in a Korean population; a multicenter cross-sectional case-control study. Clin Transl Allergy. 2022 Sep 15;12(9):e12193.

This article [1] was published with a technical error in Figure 2, a size of bars in the allopurinol-tolerant controls. The authors have re-examined the data and confirmed that this correction would not have resulted in any alteration to the results or conclusion of the paper. The figure 2 should be shown as below.

查看原文本刊更多论文

在韩国人群中，HLA-B*58:01 携带者的 HLA-A*24:02 更正会增加别嘌醇诱发的伴有嗜酸性粒细胞增多和全身症状的药物反应（DRESS）的风险；一项多中心横断面病例对照研究

M.M. Y. Kim、J. Yun、D. Y. Kang、T. H. Kim、M. K. Oh、S. Lee, et al. HLA-A* 24: 02 会增加韩国人群中 HLA-B* 58: 01 携带者发生别嘌醇诱导的伴有嗜酸性粒细胞增多和全身症状的药物反应的风险；一项多中心横断面病例对照研究。Clin Transl Allergy.2022 Sep 15;12(9):e12193.This article [1] was published with a technical error in Figure 2, a size of bars in the allopurinol-tolerant controls.作者重新检查了数据，确认这一改正不会对论文的结果或结论造成任何改变。图 2 应如下所示。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Translational Allergy Immunology and Microbiology-Immunology

CiteScore

7.50

自引率

4.50%

发文量

117

审稿时长

12 weeks

期刊介绍： Clinical and Translational Allergy, one of several journals in the portfolio of the European Academy of Allergy and Clinical Immunology, provides a platform for the dissemination of allergy research and reviews, as well as EAACI position papers, task force reports and guidelines, amongst an international scientific audience. Clinical and Translational Allergy accepts clinical and translational research in the following areas and other related topics: asthma, rhinitis, rhinosinusitis, drug hypersensitivity, allergic conjunctivitis, allergic skin diseases, atopic eczema, urticaria, angioedema, venom hypersensitivity, anaphylaxis, food allergy, immunotherapy, immune modulators and biologics, animal models of allergic disease, immune mechanisms, or any other topic related to allergic disease.

文献相关原料

公司名称	产品信息	采购帮参考价格

Correction to HLA-A*24:02 increase the risk of allopurinol-induced drug reaction with eosinophilia and systemic symptoms (DRESS) in HLA-B*58:01 carriers in Korean population; A multicenter cross-sectional case-control study

Abstract

Correction to HLA-A24:02 increase the risk of allopurinol-induced drug reaction with eosinophilia and systemic symptoms (DRESS) in HLA-B58:01 carriers in Korean population; A multicenter cross-sectional case-control study